+ Watch AMRI
on My Watchlist
The Company is a global chemistry-based drug discovery and development company focused on identifying and developing novel biologically active small molecules with applications in the drug market.
How could anyone not be excited about a company called Albany Molecular Research? I mean it's Albany, come on! The Real World Albany? Real Housewives of Albany? No?Fine then. We'll try and look at the company on its merits instead. When I see a stock carving out new all-time lows with no sign of a plateau I start looking for reasons why the company might be going out of business, and with AMR I'm just not finding them. The company has separate and solid revenue streams from Allegra royalties and outsourced contract research. Quarterly revenues and cash reserves have been stable for at least a year, dating back to when the share price was over 6. In the midst of the 2009 decline, the stock traded at 8. Meanwhile, debt remains low and manageable.The company projects continuing stable revenues and expenses through the end of the year. Despite the instability in the economy and the markets, I have not noted a significant tendency of large or small pharmaceutical companies and biotechs to reduce their research budgets. AMR certainly seems more likely to survive the current decline than the one of early 2009, which they weathered well.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions